Cited 26 times in
Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김수정 | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 민유홍 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 양우익 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 장지은 | - |
dc.contributor.author | 정준원 | - |
dc.contributor.author | 조현수 | - |
dc.date.accessioned | 2018-07-20T08:41:56Z | - |
dc.date.available | 2018-07-20T08:41:56Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161365 | - |
dc.description.abstract | Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Hyunsoo Cho | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Soo-Jeong Kim | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Woo-Ick Yang | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Ji Eun Jang | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.18632/oncotarget.20264 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A00633 | - |
dc.contributor.localId | A00779 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A02300 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A03477 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 29152083 | - |
dc.subject.keyword | primary central nervous system lymphoma | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | programmed cell death 1 | - |
dc.subject.keyword | programmed cell death-ligand 1 | - |
dc.subject.keyword | programmed cell death-ligand 2 | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.alternativeName | Kim, Soo Jeong | - |
dc.contributor.alternativeName | Kim, Yu Ri | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.alternativeName | Suh, Chang Ok | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.alternativeName | Jang, Ji Eun | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Soo Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Yu Ri | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Suh, Chang Ok | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Jang, Ji Eun | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.citation.volume | 8 | - |
dc.citation.number | 50 | - |
dc.citation.startPage | 87317 | - |
dc.citation.endPage | 87328 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, Vol.8(50) : 87317-87328, 2017 | - |
dc.identifier.rimsid | 61283 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.